Why Is Moderna (MRNA) Stock Down -14.42% Today?
Key Takeaways
- Moderna shares pulled back 14.42% in midday trading Thursday, retreating to roughly $149.23 after closing the prior session at $174.38.
- The decline was primarily driven by profit-taking following a historic 177% single-day surge on Wednesday.
- Wednesday's rally was sparked by positive Phase 3 melanoma trial results for Moderna's personalized mRNA cancer vaccine, intismeran, developed with Merck.
- Valuation concerns weighed on sentiment, with several analyst price targets remaining well below the stock's elevated trading level.
- Traders are watching for full trial data, regulatory next steps, and potential short-covering dynamics as the stock consolidates.
Opening Summary
Moderna, Inc. (MRNA), the Cambridge, Massachusetts-based biotechnology company best known for its mRNA-based medicines and COVID-19 vaccine, saw its shares fall sharply on Thursday, down 14.42% to around $149.23 in midday trading. The move follows Wednesday's extraordinary rally, in which the stock more than doubled, closing at $174.38 from a prior close of $62.96. The decline marks a classic give-back phase after a parabolic move, as investors lock in gains and reassess whether the post-breakthrough valuation is sustainable.
Profit-Taking After a Historic Surge
The primary driver behind Thursday's slide is straightforward: profit-taking. On Wednesday, MRNA shares soared 177% — the largest single-day gain in the company's history — after Moderna and partner MRK (Merck) announced that their personalized mRNA cancer vaccine, intismeran autogene, succeeded in the Phase 3 INTerpath-001 trial in high-risk melanoma patients. The combination therapy, given alongside Merck's blockbuster immunotherapy Keytruda, met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.
When a stock gaps up nearly threefold in a single session, a portion of the gains is frequently driven by momentum and forced short-covering rather than long-term institutional accumulation. The subsequent session often sees those fast-money positions unwind, which is exactly what unfolded Thursday as early buyers booked profits into the enormous run-up.
Valuation and Analyst Skepticism
A second factor pressuring the stock is the widening gap between the share price and Wall Street's fundamental views. Even as several firms issued upgrades in the wake of the data — Bank of America, for instance, moved to a Neutral rating with a $170 price objective — most revised targets still sat below Wednesday's closing price. Others, including Citi's $60 target, implied substantial downside, reflecting the fact that the companies have not yet disclosed the magnitude of the treatment benefit and that approval and commercialization remain years away.
The valuation debate is underscored by Moderna's underlying financials. The company remains unprofitable, reporting a net loss of $782 million in the second quarter of 2026 on revenue of just $145 million. While the cancer program dramatically de-risks the long-term story, the market is now pricing in years of successful commercialization before meaningful oncology revenue arrives — a setup vulnerable to near-term mean reversion.
Short Squeeze Unwind and Technical Overextension
The technical backdrop also favored a pullback. Moderna entered Wednesday's session with elevated short interest — reported around 13.5% of free float — which amplified the upside as bears were forced to cover. With that squeeze largely played out, the marginal buyer thinned on Thursday. Daily momentum indicators had reached extreme overbought territory, with the relative strength index (RSI) spiking well above 90, a level that historically precedes consolidation or corrective action as short-term traders take money off the table.
Market Context and Trading Activity
Trading activity remained elevated relative to Moderna's historical average. Wednesday's session saw volume surge to nearly 98 million shares, versus a typical daily range of roughly 2.5 million to 5 million shares in recent weeks, and Thursday's action continued to reflect heavy turnover as the broader biotech complex digested the news. The move has also rippled across the sector: on Wednesday, rival mRNA developers and cancer-vaccine peers rallied in sympathy, with BioNTech (BNTX) jumping more than 20%, while biotech-focused ETFs including the SPDR S&P Biotech ETF (XBI) and the ARK Genomic Revolution ETF (ARKG) posted outsized gains. Thursday's retracement in MRNA reflected a natural cooling of that sector-wide enthusiasm rather than any company-specific negative development.
What Comes Next for MRNA
Looking ahead, investors will focus on the full data presentation, expected at an upcoming international medical meeting, which should reveal the exact magnitude of the recurrence-free survival benefit — a detail that will heavily influence both the bull and bear cases. The companies have signaled they intend to begin discussions with regulators within the next few months, with a potential launch seen as early as 2027. Additional readouts across the broader INTerpath clinical program, spanning lung, kidney, and bladder cancers, will also be closely watched. Key risks include the possibility of a weaker-than-expected hazard ratio in the full dataset, slower-than-anticipated regulatory timelines, and continued volatility as the stock searches for a new equilibrium after its unprecedented move.
Trending AI Robots
For traders looking to navigate fast-moving situations like this one, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing AI trading bots. Tickeron provides hundreds of AI-driven trading bots covering thousands of tickers, but only those delivering the best results under current market conditions are featured in this section. Each bot differs by strategy, timeframe, performance metrics, and the symbols it trades. Explore the Trending AI Robots page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
MRNA's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for MRNA moved out of overbought territory on August 26, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In 22 of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MRNA entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on MRNA as a result. In 66 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The 10-day moving average for MRNA crossed bullishly above the 50-day moving average on August 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +9.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 213 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.099) is normal, around the industry mean (25.929). P/E Ratio (26.455) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (437.043).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement